Your browser doesn't support javascript.
loading
Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.
Boel, Judith A; de Bie, Rob M A; Schmand, Ben A; Dalrymple-Alford, John C; Marras, Connie; Adler, Charles H; Goldman, Jennifer G; Tröster, Alexander I; Burn, David J; Litvan, Irene; Geurtsen, Gert J.
Afiliación
  • Boel JA; Department of Neurology Amsterdam UMC Location University of Amsterdam Amsterdam The Netherlands.
  • de Bie RMA; Department of Psychology University of Amsterdam Amsterdam The Netherlands.
  • Schmand BA; Department of Neurology Amsterdam UMC Location University of Amsterdam Amsterdam The Netherlands.
  • Dalrymple-Alford JC; Amsterdam Neuroscience Amsterdam The Netherlands.
  • Marras C; Department of Psychology University of Amsterdam Amsterdam The Netherlands.
  • Adler CH; Department of Medical Psychology Amsterdam UMC Location University of Amsterdam Amsterdam The Netherlands.
  • Goldman JG; New Zealand Brain Research Institute and School of Psychology, Speech and Hearing University of Canterbury Christchurch New Zealand.
  • Tröster AI; Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital University of Toronto Toronto Canada.
  • Burn DJ; Arizona Study of Aging and Neurodegenerative Disorders, Mayo Clinic Arizona, Scottsdale, Arizona, USA and Banner Sun Health Research Institute Sun City Arizona USA.
  • Litvan I; Department of Physical Medicine and Rehabilitation and Neurology Shirley Ryan AbilityLab and Northwestern University Chicago Illinois USA.
  • Geurtsen GJ; Department of Clinical Neuropsychology and Center for Neuromodulation Barrow Neurological Institute Phoenix Arizona USA.
Mov Disord Clin Pract ; 9(4): 479-483, 2022 May.
Article en En | MEDLINE | ID: mdl-35582313
ABSTRACT

Background:

The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown.

Methods:

The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD.

Results:

PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II.

Conclusion:

MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Mov Disord Clin Pract Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Mov Disord Clin Pract Año: 2022 Tipo del documento: Article